Drug Trial Radar · NCT05130450
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)
Last checked: Nov 20, 2026Latest source record: Dec 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Actual
Start
Nov 18, 2021
Primary completion
Feb 2028
Study completion Feb 2028
Sponsor
- Lead sponsor
- Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
- Sponsor type
- Industry
- First posted
- Nov 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of olezarsen (formerly known as AKCEA-APOCIII-LRx) on the percent change in fasting triglycerides (TG) from baseline.
Conditions
- Familial Chylomicronemia Syndrome
Interventions
OlezarsenDrug
Olezarsen will be administered by SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Fasting TG at 6 Months (Average of Weeks 23, 25, and 27) Compared to BaselineTime frame: Baseline and 6 months
Locations
27 sites in 11 countries. Site status is shown where the registry gives one.
Diabetes/Lipid Management & Research Center
Huntington Beach, California
Excel Medical Clinical Trials, LLC
Boca Raton, Florida
Department of Pharmacy
Park Ridge, Illinois
University of Kansas Medical Center (KUMC)
Kansas City, Kansas
CTSI Investigational Pharmacy
New York, New York
Milstein Hospital
New York, New York
IDS Central
Philadelphia, Pennsylvania
Ecogene-21
Chicoutimi, Quebec, Canada
Institute de Recherches Cliniques de Montreal
Montreal, Quebec, Canada
Nathalie Saint-Pierre
Montreal, Quebec, Canada
Clinique des Maladies Lipidiques de Quebec Inc.
Québec, Quebec, Canada
Groupement Hospitalier Est- Pharmacie Secteur Essais Clinique
Bron, France
Hôpital Bicêtre
Le Kremlin-Bicêtre, France
Pharmacie Hopital de la Conception
Marseille, France
Via Sergio Pansini 5
Naples, Italy
UOC di Farmacia AOUP PAOLO GIACCONE
Palermo, Italy
Azienda Ospedaliero Universitaria Policlinico Umberto I
Rome, Italy
Academisch Medisch Centrum Goederenontvangst Apotheek t.a.v. Kenniscentrum
Amsterdam, Noor-Holland, Netherlands
Oslo Hospital Pharmacy Rikshospitalet
Oslo, Norway
Hospital da Senhora da Oliveira Guimaraes
Creixomil, Portugal
Dra Margarida Falcao Centro Hospitalar Lisboa Ocidental Hospital Egas Moniz
Lisbon, Portugal
Metabolicke centrum MU
Bratislava, Slovakia
Hospital Clínic Barcelona C/ Villarroel
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Virgen del Rocío
Seville, Spain
Apokteket AB
Malmö, Sweden
Royal Manchester Children's Hospital
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.